RFCA
PTCT icon

R&F Capital Advisors’s PTC Therapeutics PTCT Stock Holding History

R&F Capital Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		$202K Buy
+20,548
New +$249K 0.05% 555

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JGC
J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

R&F Capital Advisors's PTCT Position: Q1 2017 in Review

R&F Capital Advisors opened a new position in PTC Therapeutics (PTCT) in Q1 2017: 20,548 shares worth $202K. The stake represents 0.05% of the portfolio and ranks #555 among its holdings.

115 funds tracked by Wall St. Rank hold PTCT as of Q1 2017.

  • R&F Capital Advisors held 20,548 shares of PTC Therapeutics worth $202K as of Q1 2017.
  • PTC Therapeutics was a new R&F Capital Advisors position in Q1 2017.
  • PTC Therapeutics made up 0.05% of R&F Capital Advisors's portfolio in Q1 2017, its #555 holding.
  • 115 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2017.

Based on R&F Capital Advisors's 13F filing for Q1 2017, filed 15 May 2017.